Breast cancer survivors may not need mammograms every year: study - New York Post
- Breast cancer survivors may not need mammograms every year: study New York Post
- Study Suggests Less Frequent Mammograms Just as Effective as Annually SurvivorNet
- Breast cancer survivors may not need so many mammograms after surgery, UK study suggests Jamaica Observer
1 year 4 months ago
Transforming creative tools into instruments of empowerment
The Creative Writing Poetry Workshops were funded and supported by UN Women through the Grenada Spotlight Initiative to End Violence Against Women and Girls
View the full post Transforming creative tools into instruments of empowerment on NOW Grenada.
1 year 4 months ago
Arts/Culture/Entertainment, Community, Health, PRESS RELEASE, grenada spotlight initiative, heon project, jenella edwards, liz hamlet, seville francis, wag, writers association of grenada
The biotech news you missed from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello from ASH! Writing this Readout from a press room at the annual hematology confab here in San Diego. Today’s edition is chockfull of Vertex content, plus some extras from ASH and elsewhere.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello from ASH! Writing this Readout from a press room at the annual hematology confab here in San Diego. Today’s edition is chockfull of Vertex content, plus some extras from ASH and elsewhere.
1 year 4 months ago
Biotech, Business, Health, Pharma, Politics, The Readout, biotechnology, Cancer, drug development, drug pricing, FDA, finance, genetics, Pharmaceuticals, Research
STAT+: The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds
During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $1.2 billion last year, according to a new report.
The drug for which spending increased the most due to a price increase was Humira, which is used to treat rheumatoid arthritis, plaque psoriasis, and other disorders. AbbVie raised the wholesale price by 7.1%. The net price — after rebates and discounts — rose by 1.9%, most likely because the company offered more concessions than previously.
Consequently, spending for this drug climbed by $386 million, according to the report issued by the Institute for Clinical and Economic Review, a nonprofit that assesses the cost-effectiveness of medicines. The report noted that the manufacturer disputed the findings, calling the methodology “flawed” and arguing that the analysis was “subjective.”
1 year 4 months ago
Pharma, Pharmalot, drug pricing, Pharmaceuticals, STAT+
‘Unequivocal’ data emerges from trial of CLL therapy guided by measurable residual disease
SAN DIEGO — A combination of targeted therapies used for a response-directed duration significantly improved outcomes compared with chemoimmunotherapy for fit patients with untreated chronic lymphocytic leukemia, according to study results.Ibrutinib (Imbruvica; Janssen, Pharmacyclics) plus venetoclax (Venclexta; AbbVie, Genentech) reduced risk for death by 69%, findings presented at ASH Annual
Meeting and Exposition showed.“The survival curves are very impressive — in fact, I don’t think they could’ve been much better given we conducted this trial during a pandemic,”
1 year 4 months ago
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
Zydus, Daewoong Pharma collaborate to co-develop, commercialise Leuprolide Long-Acting Injectable in US
Ahmedabad: Zydus Worldwide DMCC,
a wholly owned subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical Co., Ltd. has announced that they have entered into an exclusive licensing agreement to co-develop and
commercialize Leuprolide Acetate for Depot Suspension (RLD: Lupron Depot, AbbVie) in
six dosage strengths for the United States (US) market.
Ahmedabad: Zydus Worldwide DMCC,
a wholly owned subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical Co., Ltd. has announced that they have entered into an exclusive licensing agreement to co-develop and
commercialize Leuprolide Acetate for Depot Suspension (RLD: Lupron Depot, AbbVie) in
six dosage strengths for the United States (US) market.
Under the terms of the agreement, Zydus will assume full responsibility for the clinical
development and commercialization in the US market, and Daewoong will be responsible for
the pre-clinical studies, production and supply of the product. Daewoong, utilizing its
proprietary technology, will produce Leuprolide Acetate for Depot Suspension in its
manufacturing facilities located in Osong, South Korea.
The exclusive agreement also includes
development, regulatory, and commercialization milestone payments based on the successful
outcome. Additionally, this agreement also includes a profit share on future sales between the
two companies.
Speaking about the development, Managing Director of Zydus Lifesciences Ltd., Dr. Sharvil
Patel said, “Enabling access to affordable generic versions for patients in the US has been our
ongoing commitment. This is an important milestone and we are happy to work with Daewoong
for generic version of Lupron Depot, empowering patients with the access to a critical therapy.
This is yet another step to strengthen the Zydus’ complex injectable portfolio.”
“Given the complexity, complex generic drug products like Lupron Depot do not exist to date
and we aim to be the first company in manufacturing the generic version of this complex, longacting injectable Lupron Depot product,” said Sengho Jeon, Chief Executive Officer,
Daewoong Pharmaceutical. “We are delighted to enter into this exclusive licensing agreement
with Zydus as part of our plan to develop and commercialize long-acting injectable of
Leuprolide Acetate.”
Leuprolide acetate for depot suspension is a gonadotropin-releasing hormone (GnRH) agonist,
a long-acting injectable product in a kit with a prefilled dual-chamber syringe, used for the
treatment of advanced prostatic cancer, endometriosis, and uterine leiomyomata (fibroids)
depending on its dosage regime. Leuprolide acetate for depot suspension had annual sales of
approximately $671 million in the US with a growth rate of 10%, according to IQVIA data
MAT Oct-2023.Read also: Zydus Lifesciences US arm concludes asset transfer of CUTX-101 for Menkes disease from Cyprium Therapeutics
1 year 4 months ago
Blog,News,Industry,Pharma News,Latest Industry News
Health Archives - Barbados Today
Fogging programme continues this week
The Vector Control Unit will continue its fogging programme this week with emphasis on three parishes.
The Vector Control Unit will continue its fogging programme this week with emphasis on three parishes.
When the exercise starts on Monday, December 11, the team will focus attention on the St John districts of Foster Hall, St Margaret’s Village Road, Glenburnie and the environs.
A return to that parish on Tuesday, December 12, will see fogging at Martin’s Bay, Zores, New Castle, New Castle Hill, and environs.
The following day, Wednesday, December 13, the team will journey to St Philip, where Bottom Bay Road, Bottom Drive, Ocean Drive, Apple Hall, Inch Cape, Harrismith Road, and environs will be sprayed.
On Thursday, December 14, fogging will move to St Michael. Areas to be sprayed are: Danesbury Road, Hinkson Gap, Retreat Road, Spring Garden, Carters Gap, Carlton Terrace, Brighton Beach Road North and South and environs.
Fogging concludes on Friday, December 15, with a return to St Michael. The districts to be visited are Brighton Road, Ashdeane Road, Brighton Terrace, Dodson Land, Rosemont, Deacon’s Farm Housing Area, Birds River, Holders Land, Brandons, Bays Water, and environs.
Fogging will run from 4:30 to 8:30 p.m., each day. Householders are asked to assist in the control of the aedes aegypti mosquito by opening all windows and doors to allow the fog to penetrate. Persons with respiratory problems should protect themselves from inhaling the fog.
Pedestrians and motorists should proceed with caution when encountering fogging operations on the street and parents are instructed to prohibit children from playing in the fog or running behind the fogging machine.
Members of the public are advised that the completion of scheduled fogging activities may be affected by events beyond the Unit’s control. In such circumstances, the Unit will return to affected communities as soon as possible.
(PR)
The post Fogging programme continues this week appeared first on Barbados Today.
1 year 4 months ago
A Slider, Health, Local News
Marijuana and heart disease
MARIJUANA has been used in human societies for over 6,000 years. For much of the last 100 years it has been viewed as a drug of abuse, its use restricted and illegal in much of the world.
However, in many countries including ours it has remained popular for recreational, medical, and religious uses. More recently there has been a trend worldwide towards legalising the use of marijuana for personal consumption. Along with this change studies have found medical uses for marijuana and proven it's relative safety for recreational consumption particularly when compared to other drugs of abuse. There have, however, been signals of potential harm for the heart and vascular system from the use of marijuana. It's important to note that given the grey legal status of marijuana use at the federal level in the United States and in many European countries, it is difficult for researchers to conduct large safety studies as with legal drugs. However, large-scale observational studies involving thousands of patients have begun to appear and have been presented at cardiology meetings this year.
When we speak of the use of marijuana, we are not referring to one chemical agent but rather hundreds of chemicals that are present in the plant which have the potential to cause physiological effects. Currently cannabinoids are thought to be responsible for most of the effects on the brain and more than 100 of these compounds have been identified. The two most well studied are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC appears to be responsible for more of the psychoactive effects of marijuana while CBD is thought to help with relaxation and pain control. Marijuana can be cultivated to have higher or lower absolute and relative levels of THC and CBD which can influence the overall effect of the plant on the user.
Beneficial effects of marijuana
Multiple studies have documented that the use of marijuana can have beneficial effects. These include pain relief, particularly in neuropathic pain, cancer-related pain and fibromyalgia. Marijuana also improves symptoms of nausea and vomiting and can be useful in patients who are receiving chemotherapy. It has been used in the treatment of spasticity in multiple sclerosis and for some types of epilepsy. Our own University of the West Indies developed a medicine for glaucoma using extracts from the marijuana plant. There is some evidence that marijuana may be useful in the management of opioid withdrawal. The use of marijuana has been proposed in several other diseases for which the evidence of significant benefit is not clear cut, including anxiety/depression, Alzheimer's disease, cancer, inflammatory bowel disease, Parkinson's disease, and sleep disturbances.
Physiological effects of marijuana on the heart and vascular system
The chemicals in the marijuana plant have many effects on the heart and vascular system. It is important to realise that most of the data that we have in this regard comes from the study of THC and CBD. The effects of the other cannabinoids are not well understood. Our bodies produce several cannabinoids that have physiological effects and thus we have receptors through which these endogenous cannabinoids act. These receptors can be affected by THC and CBD. The interactions can be quite complex with THC acting directly on receptors and CBD playing more of a regulatory role and modifying the effect of THC or other cannabinoids that are produced in the body. Cannabinoid receptors are present in many tissues including the heart and vascular system, the gastrointestinal tract, the immune system, and the brain. The effects on the heart and vascular system can be quite varied depending on the route of administration. (smoking vs ingestion), the relative ratio of THC vs CBD that is absorbed and the potency or the amount of cannabinoids that are taken.
A variety of physiological and pathological effects have been described because of the binding of THC and CBD. THC has been noted to activate the fight or flight system, cause abnormal growth in heart muscle and vascular cells, increase inflammation in heart vessels and to increase toxic chemicals in the heart and blood vessels. Whereas CBD has been noted to suppress the activation of inflammatory cells and chemicals. These somewhat antagonistic effects have led some to hypothesise that THC increases the risk of heart and vascular disease while CBD attenuates it.
Acute clinical effects of marijuana use on the heart
Aside from the psychological effects, marijuana has acute effects on the heart and vascular system which can be complicated given the different effects of THC and CBD. When the effect of THC predominates (as in most patients who are using marijuana for its euphoric effects), there is an increase in heart rate and blood pressure. The amount of oxygen required by heart muscle increases and there is evidence for an increase in abnormalities in the vessel walls with greater risk of clot formation. In patients using marijuana with higher CBD effects the heart rate and blood pressure fall and blood vessels dilate. In some diabetic models the CBD effect results in reduced vessel inflammation.
General concerns for the heart and blood vessels
The absence of large gold standard studies, the multiple ways in which marijuana is used and the fact that there is a great variety of strains with differing levels of THC and CBD along with limited data on other cannabinoids present in the plant make definitive general statements challenging. One trend that has been clear is the rise in the amount of THC which is present in marijuana plants. This has been well documented in the studies in the United States. Data from a study in Colorado found that in the 1970s the average THC concentration in the marijuana plant was less than three per cent. Currently levels of 14 per cent can be found in some varieties. Given the cardiac and vascular effects of THC this potentially may be a clinical issue. Another concern is the effects of combustion on the chemicals in the marijuana plant in those who smoke marijuana. It has been documented that the amount of carboxyhemoglobin (a protein that interferes with the distribution of oxygen throughout the body) increases by five-fold after smoking. Tar, which is a chemical produced by combustion of plant materials and which has been well studied in cigarettes, is also present in smoking marijuana rising by three-fold from baseline. Tar has been associated with lung damage, vascular damage and cancer risk in cigarette smokers and may well be an issue in those who smoke marijuana.
Aside from these general concerns, studies have been done over many years raising the question of heart and vascular damage in those who smoke marijuana. These initial reports were generally small and short term. However, larger observational studies are now being conducted and reported. We will review these clinical studies in our article next week.
Dr Ernest Madu, MD, FACC and Dr Paul Edwards, MD, FACC are consultant cardiologists for Heart Institute of the Caribbean (HIC) and HIC Heart Hospital. HIC is the regional centre of excellence for cardiovascular care in the English-speaking Caribbean and has pioneered a transformation in the way cardiovascular care is delivered in the region. HIC Heart Hospital is registered by the Ministry of Health and Wellness and is the only heart hospital in Jamaica. Send correspondence to info@
caribbeanheart.com
or call 876-906-2107.
1 year 4 months ago
Chevening alumni launches adolescent mental health campaign
IN response to escalating mental health challenges faced by young Jamaicans, Jamaica Chevening Alumni Network, with endorsement from the Ministry of Health and Wellness (MOHW) and the British High Commission, has launched a mental awareness campaign, #YourMindMatters.
The initiative, which is funded by the UK's Foreign, Commonwealth, and Development Office, is strategically designed to destigmatise mental illness and prioritise the mental well-being of the younger generation. It aims to impact Jamaican children and teenagers, aged 10-19, through a multifaceted approach.
This includes a robust multimedia awareness campaign aimed at changing negative perceptions about mental health, a day-long conference for students and parents, introduction of a mental health curriculum into selected schools, and collaborative partnerships with key stakeholders across Jamaica.
Speaking at the media launch of the Adolescent Mental Health Conference on Monday, Health Minister Dr Christopher Tufton emphasised the urgency of normalising mental health and debunking societal stigmas.
"In our society mental health is often narrowly defined, making it a topic people avoid and even stigmatise. This narrow perspective leads to harmful actions like isolating and ostracising those with mental health issues, creating an inextricable link between mental health challenges and homelessness.
"The solution lies in changing this approach. Ideally, we should aim to make mental health a normal and accepted part of our conversations and support systems, rather than isolating and rejecting those who need help," he stated.
With a population of over 800,000 children in Jamaica the minister estimates that, conservatively, about 15 per cent — equivalent to nearly 120,000 children — may be grappling with a mental disorder. Further, he points out that five per cent, or approximately 40,000 children, could be experiencing the more severe impacts of mental health disorders.
Chevening alumna and #YourMindMatters chief project lead, Najequa Barnes expressed similar views, echoing the need for more support services for Jamaican youth.
"Our adolescents are our present and future, and they face unique issues within their community. Our approach to providing support will require the inclusion of stakeholders at all levels — within their homes, churches, clubs, civil society, as well as public and private partnership."
She continued: "Our journey takes us beyond a mere launch; it introduces us to a comprehensive conference that seeks to address the critical issue of adolescent mental health. This conference aims to provide training and support to both students and parents — a holistic approach that recognises the integral role played by schools and families in nurturing the mental well-being of our youth."
Meanwhile, British High Commissioner to Jamaica Judith Slater extended her organisation's support for the project as she delivered her remarks at the launch event.
"The #YourMindMatters campaign is a timely and relevant initiative addressing critical mental health challenges among Jamaican youth. Our team is delighted to support this impactful project, spearheaded by our Chevening alumni in partnership with the Ministry of Health and Wellness. We extend our best wishes for great success, recognising the importance of fostering mental well-being for the future leaders of Jamaica," she said.
The Adolescent Mental Health Conference, which is set for Saturday, January 13, 2024 at Jamaica Conference Centre, aims to provide mental health sensitisation and training to 100 Jamaican parents/guardians and children. The event will feature a team of experts, including psychiatrists and psychologists, who will impart strategies and tips to parents as a means of helping them identify and address mental health challenges in their own children.
Additionally, the Ministry of Health and Wellness, which assumes a pivotal role in fostering mental health awareness among youth, will collaborate with the Ministry of Education and Youth (MOEY) to guide 50 students, 10 each from five schools, through specialised mental awareness training using the MOEY's mental health curriculum.
To extend its reach, the Adolescent Mental Health conference will be live-streamed via the social media handle @Mindfulness Jamaica to facilitate access by other schools and interested parties.
Minister Tufton noted the importance of providing this kind of support: "Helping young people develop basic skills to cope with challenges, steering them away from substance abuse, and encouraging problem-solving not only prepares them for inevitable pressures but also fosters resilience. Creating a safe space for relaxation and open communication ensures they can effectively navigate difficulties, ultimately contributing to a healthier and more capable generation," he explained.
Similarly, Barnes urges a shift from viewing adolescents through the lens of deviant behaviour to understanding the nuances of their experiences, stating: "Their well-being needs to be treated as priority, fully integrated and at the forefront of policy. No longer should we approach our adolescents with an ideology of deviant behaviour but should seek to educate ourselves on the matters unique to them."
The Chevening alumni invites interested groups and corporate sponsors to come on board for the project in order to make the conference as impactful as possible. By providing financial assistance, organisations contribute directly to destigmatising mental health, enhancing awareness, and fostering a supportive environment for adolescents in Jamaica.
1 year 4 months ago
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
AYUSH treatment on par with Allopathic treatment for Reimbursements: HC
Chennai: The Madras High Court recently asked the Insurance Regulatory and Development Authority of India (IRDAI) to treat AYUSH treatment on par with Allopathic treatment while reimbursing expenses incurred during treatment.
IRDAI has also been directed to reimburse the insurance amount on equal scales for both branches of medicine. "There shall be a direction to the third respondent to act upon the suggestion made by this Court to place AYUSH treatment on par with alopathic treatment and direct the insurance companies to reimburse the insurance amount on equal scales," ordered the HC bench comprising Justice N. Anand Venkatesh.
The HC bench also referred to the COVID-19 pandemic and pointed out that during the pandemic, traditional medicines were recommended for the infected persons. Effective treatment was provided under AYUSH, which provided substantial relief to the patients, noted the HC bench.
"In such circumstances, it will not be reasonable to restrict the cap and thereby deprive the policy holders to get reimbursement of the amount, which was spent by them in AYUSH hospitals," opined the Court.
At this outset, the court also reminded the IRDAI that patients can choose the type of treatment that is required for them and they have an option to either choose alopathic medicines or go for traditional medicines provided by AYUSH.
Therefore, the court opined that whatever expenses are incurred for either of these treatments must be placed on equal scales. "It will be discriminatory to give preference to allopathy as against AYUSH treatment. This must be kept in mind by the third respondent whenever the policies are drafted and sent for approval," it noted.
The Court also expressed its opinion that traditional treatment in India, which falls under the head of AYUSH treatment must also be encouraged and it must get the same weightage as is given to allopathic treatment. Therefore, a person , who chooses to undergo AYUSH treatment should be entitled to receive the insurance amount towards the expenses incurred by him, as is done to a patient who undergoes allopathic treatment. "This has to be implemented by the third respondent in all future policies," the Court noted in its order.
These observations were made by the High Court while considering two petitions seeking full reimbursement of the amount claimed by the petitioners under their respective Insurance Policies.
One of the pleas was filed by an Advocate who had taken a policy for a sum of Rs 5 lakhs and the other one was filed by a clerk who took a policy for a sim of Rs 4 lakhs.
Both of them got infected with COVID-19 and sought treatment at Siddha Hospital. Both of them sought a reimbursement of Rs 52,250 each which was incurred in treatment. However, only Rs 15,000 and Rs 10,000 were reimbursed to them.
They submitted that when they took the policies in the year 2009, it did not provide for any separate cap for reimbursement towards treatment taken in AYUSH Hospital, and the same was treated on par with Allopathy treatment. Therefore, it was contended that whatever amount was spent towards the treatment in Siddha Hospital must be reimbursed by the Insurance Company.
On the other hand, the insurance company submitted that the Policies are governed by the regulation issued by IRDA from time to time and as per the same, a maximum cap is fixed on the maximum amount of reimbursement for AYUSH treatment.
As per the Insurance Company, IRDAI policy states, that for a sum of Rs 5 lakh, a maximum of Rs 15,000 and for a sum of Rs 4 lakhs, a maximum sum of Rs 10,000 can be reimbursed. Referring to these, the company submitted that the said amount had already been reimbursed to the petitioner.
While considering the policies, the HC bench noted that under the policy, the expenses incurred for the treatment under the system of medicines other than allopathy were excluded. The court also took note of the fact that the maximum amount of reimbursement allotted to the petitioner under the respective caps for AYUSH treatments had been disbursed to the petitioners and no further directions could be given to the Insurance Company.
However, the Court took note of a larger issue and highlighted the discrimination in the policies in respect of AYUSH and allopathic treatment. Highlighting the service provided by AYUSH treatment during COVID-19 pandemic, the bench noted, "During Covid-19 pandemic, it is the traditional medicines that were recommended for the infected persons and the hospitals were only attending to emergency cases by providing support system, obviously, since allopathy did not have any medicine to treat covid-19 patients. It is true that such an eventuality would not have been anticipated at the time of finalizing the policy. That is the reason why the maximum cap was fixed under the policy. However, it came to light that the effective treatment was also given to the infected persons under AYUSH and it provided substantial relief to the patients. In such circumstances, it will not be reasonable to restrict the cap and thereby deprive the policy holders to get reimbursement of the amount, which was spent by them in AYUSH hospitals."
"The IRDAI must take into consideration the fact that patients can choose the type of treatment that is required for them and they have an option to either choose alopathic medicines or go for traditional medicines provided by AYUSH. Whatever expenses are incurred for either of these treatments must be placed on equal scales. It will be discriminatory to give preference to allopathy as against AYUSH treatment. This must be kept in mind by the third respondent whenever the policies are drafted and sent for approval," the Court further noted.
Directing IRDAI to draft future policies while giving equal importance to AYUSH treatment, the bench noted, "The third respondent must bear in mind that the traditional treatment in India which falls under the head of AYUSH treatment must also be encouraged and it must get the same weightage as is given to alopathic treatment and a person, who chooses to undergo AYUSH treatment should be entitled to receive the insurance amount towards the expenses incurred by him, as is done to a patient who undergoes alopathic treatment. This has to be implemented by the third respondent in all future policies."
At this outset, the bench recorded the submission by the Insurance Company that it has now come up with a new policy called as AYUSH plan policy, wherein even AYUSH treatment is covered and the expenses incurred for the treatment get reimbursed.
"By virtue of this new policy, AYUSH treatment has been brought on par with the alopathic treatment," noted the court while directing IRDAI to act upon the suggestion of the bench to place AYUSH treatment on par with Allopathic treatment and direct the insurance companies to reimburse the insurance amount on equal scales.
To read the order, click on the link below:
https://medicaldialogues.in/pdf_upload/madras-hc-reimbursement-227200.pdf
1 year 4 months ago
AYUSH,Blog,Editors pick,State News,News,Tamil Nadu,Ayurveda,Ayurveda News
Health Archives - Barbados Today
QEH: New measures in place for burning medical waste at Martindales Road facility
The Queen Elizabeth Hospital (QEH) says it resumed burning medical waste at its Martindales Road facility on Monday, November 27.
The Queen Elizabeth Hospital (QEH) says it resumed burning medical waste at its Martindales Road facility on Monday, November 27.
Since then, management has received a number of complaints from residents in the surrounding environs about the increase in the level of smoke coming from the incinerator, the QEH said in a statement on Saturday.
The hospital said it has acknowledged these concerns and is taking them seriously.
In response, management and the engineering department have decided on the following measures:
- The creation of a new schedule for burning medical waste as an immediate measure to address environmental concerns raised by residents. Starting next week, incineration will be conducted on Tuesdays, Wednesdays and Thursdays only; there will be no burning from Friday through to Monday.
- As a temporary measure, the existing incinerator will be outfitted with new ‘after-burners’, the purpose of which is to provide a cleaner burn and a significant reduction in the level of smoke expelled from the plant. These should be installed within the coming weeks.
- The board of management and the management team are actively exploring green, environmentally friendly technologies as a long-term solution for medical waste management at the hospital.
Management at the Queen Elizabeth Hospital apologies for the inconvenience and thanks residents for their patience and understanding, as we work on a more permanent solution.
(PR)
The post QEH: New measures in place for burning medical waste at Martindales Road facility appeared first on Barbados Today.
1 year 4 months ago
A Slider, Health, Local News
Health Archives - Barbados Today
Rise in dengue cases
The Best-dos Santos Public Health Laboratory has reported an increase in positive samples for dengue fever in Barbados.
The Best-dos Santos Public Health Laboratory has reported an increase in positive samples for dengue fever in Barbados.
As a result, health officials are urging Barbadians to take precautions to avoid contracting the virus, which is transmitted by the Aedes Aegypti mosquito.
The laboratory indicated that five positive cases of dengue – three cases of Type 2 and two cases of Type 3 were recorded in August. Additionally, four positive cases of the virus – two cases each of Type 2 and Type 3 – were recorded, so far, for September.
This profile is somewhat different from earlier this year, when Types 1 and 3 were the main strains circulating. However, the Best-dos Santos Public Health Laboratory reported that these results were in keeping with the strains that are currently circulating in the Americas.
In light of the increase in cases, Chief Medical Officer, Dr Kenneth George, encourages members of the public to report mosquito sightings to the Environmental Health Departments at the polyclinics nearest to them.
“Once those reports are received, the environmental health officers will go out to those districts and carry out investigations,” he said.
The Ministry currently conducts fogging in “problem areas” where it receives several reports about mosquito breeding.
The CMO noted that the likelihood of severe dengue is increased when there are multiple strains of the virus circulating. He added that severe dengue can include shock syndromes and hemorrhaging.
The Ministry reminded health providers to remain vigilant for the warning signs of severe dengue, which usually occur after the fever has subsided and may include, severe abdominal pain and signs of bleeding, for example, from the gums.
“In addition, all unexplained fevers with accompanying headaches, muscle pains or rash should be reported to your primary care physician. The Best-dos Santos Public Health Lab remains on alert. It is, at this time, able to process excess samples,” Dr George explained.
He pointed out that while the Ministry of Health and Wellness remained committed to reducing the mosquito burden in the country, it could not do it alone and needed the public’s cooperation.
The Chief Medical Officer advised Barbadians to check water they have stored and indoor plants regularly for mosquito larvae, and change the water in the overflow dishes of plant pots every three to four days.
He further suggested that persons wear mosquito repellent during peak biting times – dusk and dawn; wear light-coloured, long-sleeved clothing; and inspect old tyres for water collection and drain them, once necessary.
Mosquito nets should also be used over infant beds, carriers, cribs and strollers; and window and door screens should be installed to keep out mosquitoes.
The Ministry encourages health providers to send samples from persons suspected of having dengue to the public health lab for definitive diagnosis and typing of the specific dengue strains.
(BGIS)
The post Rise in dengue cases appeared first on Barbados Today.
1 year 4 months ago
A Slider, Health, Local News
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
AbbVie to focus on smaller deals after buying spree
United States: U.S. drugmaker AbbVie said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cerevel Therapeutics and ImmunoGen.
"I would not anticipate similar sized transactions for the foreseeable future," said AbbVie's Chief Operating Officer Robert Michael on a conference call, referring to the company's $8.7 billion buyout of Cerevel Therapeutics announced on Wednesday.
Read also: AbbVie to acquire Cerevel Therapeutics for USD 8.7 billion
AbbVie said it expects to return to "robust growth" in 2025, after its recent buying spree.
"With additions of Cerevel and ImmunoGen, AbbVie is in a stronger position to deliver sustainable long-term performance in the 2030s and beyond timeframe," said the company's Chairman and CEO Richard Gonzalez.
Read also: AbbVie to acquire ImmunoGen, including its flagship cancer therapy Elahere
Some Wall Street analysts raised concerns that Cerevel's treatments under development might overlap with AbbVie's products, presenting a potential risk for the deal to get approval from the U.S. Federal Trade Commission.
Gonzalez said AbbVie has "confidence" the deal will get through the FTC.
AbbVie's Vraylar is approved for schizophrenia, bipolar disorder and major depressive disorder. The U.S. drugmaker also has its Parkinson's disease treatment Duodopa in the market and another candidate ABBV-951 in development.
"I think the schizophrenia overlap may warrant some additional scrutiny. However, it is a pretty fragmented kind of space," said BMO Capital analyst Evan Seigerman.
Read also: AbbVie to acquire Cerevel Therapeutics for USD 8.7 billion
1 year 4 months ago
Blog,News,Industry,Pharma News,Latest Industry News
Millions of US adults have chronic fatigue syndrome, CDC reports
Health officials on Friday released the first nationally representative estimate of how many U.S. adults have chronic fatigue syndrome: 3.3 million.
The Centers for Disease Control and Prevention's number is larger than previous studies have suggested, and is likely boosted by some of the patients with long COVID. The condition clearly "is not a rare illness," said the CDC's Dr. Elizabeth Unger, one of the report's co-authors.
Chronic fatigue is characterized by at least six months of severe exhaustion not helped by bed rest. Patients also report pain, brain fog and other symptoms that can get worse after exercise, work or other activity. There is no cure, and no blood test or scan to enable a quick diagnosis.
CDC'S COMMENTS ON TODAY'S PNEUMONIA OUTBREAKS VS. THE EARLY COVID CASES, AS COMPARED BY EXPERTS
Doctors have not been able to pin down a cause, although research suggests it is a body's prolonged overreaction to an infection or other jolt to the immune system.
The condition rose to prominence nearly 40 years ago, when clusters of cases were reported in Incline Village, Nevada, and Lyndonville, New York. Some doctors dismissed it as psychosomatic and called it "yuppie flu."
Some physicians still hold that opinion, experts and patients say.
Doctors "called me a hypochondriac and said it was just anxiety and depression," said Hannah Powell, a 26-year-old Utah woman who went undiagnosed for five years.
COVID VACCINATION RATES ‘ALARMINGLY’ LOW AMONG NURSING HOME STAFF, CDC SAYS: ‘A REAL DANGER’
The new CDC report is based on a survey of 57,000 U.S. adults in 2021 and 2022. Participants were asked if a doctor or other health-care professional had ever told them they had myalgic encephalomyelitis or chronic fatigue syndrome, and whether they still have it. About 1.3% said yes to both questions.
That translated to about 3.3 million U.S. adults, CDC officials said.
Among the other findings: The syndrome was more common in women than men, and in white people compared with some other racial and ethnic groups. Those findings are consistent with earlier, smaller studies.
However, the findings also contradicted long-held perceptions that chronic fatigue syndrome is a rich white woman's disease.
There was less of a gap between women and men than some previous studies suggested, and there was hardly any difference between white and Black people. The study also found that a higher percentage of poor people said they had it than affluent people.
Those misperceptions may stem from the fact that patients who are diagnosed and treated "traditionally tend to have a little more access to health care, and maybe are a little more believed when they say they're fatigued and continue to be fatigued and can't go to work," said Dr. Brayden Yellman, a specialist at the Bateman Horne Center in Salt Lake City, Utah.
The report relied on patients’ memories, without verifying their diagnoses through medical records.
That could lead to some overcounting, but experts believe only a fraction of the people with chronic fatigue syndrome are diagnosed, said Dr. Daniel Clauw, director of the University of Michigan’s Chronic Pain and Fatigue Research Center.
"It’s never, in the U.S., become a clinically popular diagnosis to give because there’s no drugs approved for it. There’s no treatment guidelines for it," Clauw said
The tally likely includes some patients with long COVID who were suffering from prolonged exhaustion, CDC officials said.
Long COVID is broadly defined as chronic health problems weeks, months or years after an acute COVID-19 infection. Symptoms vary, but a subset of patients have the same problems seen in people with chronic fatigue syndrome.
"We think it's the same illness," Yellman said. But long COVID is more widely accepted by doctors, and is being diagnosed much more quickly, he said.
Powell, one of Yellman's patients, was a high school athlete who came down with an illness during a trip to Belize before senior year. Doctors thought it was malaria, and she seemed to recover. But she developed a persistent exhaustion, had trouble sleeping and had recurrent vomiting. She gradually had to stop playing sports, and had trouble doing schoolwork, she said.
After five years, she was diagnosed with chronic fatigue and began to achieve some stability through regular infusions of fluids and medications. She graduated from the University of Utah and now works for an organization that helps domestic violence victims.
Getting care is still a struggle, she said.
"When I go to the ER or to another doctor’s visit, instead of saying I have chronic fatigue syndrome, I usually say I have long COVID," Powell said. "And I am believed almost immediately."
1 year 4 months ago
us, associated-press, coronavirus, Health
STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we do plan to tidy the grounds, promenade with the official mascots, and catch up on our reading. We also hope to hold another listening party with Mrs.
Pharmalot and the rotation will likely include this, this, this, and this. And what about you? With holidays unfolding, you could head to your local temple of consumption and give the economy a boost. You could also plan an end-of-year getaway or, perhaps, you might soak in the great outdoors with a ride in the country or a walk in the park. Well, whatever you do, have a grand time. And be safe. Enjoy, and see you soon. …
After months of deliberation, the Biden administration disclosed plans to sidestep patents in order to lower costs for some pricey medicines that were discovered with taxpayer money. But the move, which must still be finalized by an inter-agency working group, is already causing uncertainty over the extent to which drugmakers may lose valuable monopolies and consumers will save money, STAT explains. This reflects the seemingly contradictory approach the administration has taken toward the controversial concept, as well as open-ended language in the proposal. As a result, there is a mix of fear and doubt as the pharmaceutical industry and patients try to envision the eventual terms.
The $32,000 cost of a crucial drug to treat severe lead poisoning drew ire from U.S. Sen. Amy Klobuchar (D-Minn.), who wrote a letter to Rising Pharmaceuticals seeking answers on how the company reached its price, CNN says. The drug costs almost 10 times more than an imported version of the medicine from France, which the U.S. Food and Drug Administration had allowed to be used in the U.S. while the drug was in shortage. Toxicologists says the price can make it difficult for hospitals to stock the medicine, called calcium disodium EDTA, potentially leading to delays of days when patients need urgent treatment. EDTA is used for the most severe cases of lead poisoning.
1 year 4 months ago
Pharma, Pharmalot, pharmalittle, STAT+
Dr. Arturo Grullón Hospital receives state-of-the-art ventilators for newborn care
Santo Domingo.- Dr. Daniel Rivera, the Minister of Public Health, recently presented two new ventilators to the Dr. Arturo Grullón Regional Children’s Hospital, enhancing the facility’s newborn unit. This gesture aligns with President Luis Abinader’s government’s commitment to bolster public health, particularly pediatric care.
Santo Domingo.- Dr. Daniel Rivera, the Minister of Public Health, recently presented two new ventilators to the Dr. Arturo Grullón Regional Children’s Hospital, enhancing the facility’s newborn unit. This gesture aligns with President Luis Abinader’s government’s commitment to bolster public health, particularly pediatric care.
The handover of these critical devices, aimed at improving child healthcare services, was made to Dr. Mirna López, the hospital’s director. López expressed gratitude for the ventilators, emphasizing their importance in advancing the health of the children in the region.
“These ventilators will enable us to offer high-quality and timely care to pediatric patients in our reference center for the Cibao region,” Dr. López stated. The ventilators are described as state-of-the-art, equipped with features essential for the safe and effective treatment of pediatric patients.
The donation ceremony saw attendance from officials of the provincial Public Health Directorate in Santiago, the Norcentral Health Regional Directorate, and departmental managers from the Arturo Grullón Hospital.
1 year 4 months ago
Health
UKHSA encourages eligible people from ethnic minority groups to book their flu and COVID-19 vaccines
UKHSA is strongly encouraging eligible people from ethnic minority groups, particularly people from the Pakistani and black Caribbean ethnic groups and individuals living in more deprived areas, to book their flu and COVID-19 vaccines.
UKHSA is strongly encouraging eligible people from ethnic minority groups, particularly people from the Pakistani and black Caribbean ethnic groups and individuals living in more deprived areas, to book their flu and COVID-19 vaccines.
1 year 4 months ago
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
Why worry about diabetes & is it true you can't eat fried foods if you have diabetes? - Dr Mary D Cruz
Diabetes is a chronic condition characterized by elevated blood sugar levels due to insufficient insulin production or the body's inability to utilize insulin effectively. It's crucial to worry about diabetes due to its potential complications, including heart disease, nerve damage, vision problems, kidney issues, and more.
Regarding the myth that individuals with diabetes can't eat fried foods, it's important to note that while fried foods are generally high in unhealthy fats and can spike blood sugar levels, moderation and wise choices are key. People with diabetes can include occasional fried foods in their diet but should focus on healthier cooking methods like baking, grilling, or air frying to minimize the intake of unhealthy fats. Portion control, choosing healthier oils, and balancing fried foods with a well-rounded diet comprising plenty of vegetables, whole grains, lean proteins, and fruits are essential for managing blood sugar levels in diabetes. Consulting a healthcare professional or a dietitian for personalized dietary advice is recommended for individuals with diabetes.
In this video Dr Mary D Cruz, Consultant Physician and Diabetologist at Ben Nevis Clinic, Kolkata, elucidates the nature of diabetes and its significance while debunking the misconception surrounding dietary restrictions, particularly regarding fried foods, for individuals with diabetes.
1 year 4 months ago
Diabetes and Endocrinology,Diabetes and Endocrinology Videos,MDTV,Diabetes and Endocrinology MDTV,MD shorts MDTV,Diabetes & Endocrinology Shorts
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
AbbVie to acquire Cerevel Therapeutics for USD 8.7 billion
North Chicago: AbbVie Inc. and Cerevel Therapeutics have announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.
The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across psychiatric and neurological disorders where significant unmet needs remain for patients.
Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024, subject to Cerevel shareholder approval, regulatory approvals, and other customary closing conditions.
"Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "AbbVie will leverage its deep commercial capabilities, international infrastructure, and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets."
"Cerevel has always been committed to transforming what is possible in neuroscience. With AbbVie's long-standing expertise in developing and commercializing medicines on a global scale, Cerevel's novel therapies will be well positioned to reach more people living with neuroscience diseases," said Ron Renaud, president and chief executive officer, Cerevel Therapeutics. "The talented, passionate, and dedicated Cerevel team has made great progress over the past five years in developing our innovative suite of potential medicines, and we are pleased that AbbVie has recognized the tremendous potential of our pipeline. This acquisition reinforces the renaissance we are seeing in neuroscience, and we are proud to be at the forefront."
Cerevel's late-stage asset emraclidine, a positive allosteric modulator (PAM) of the muscarinic M4 receptor, is a potential best-in-class, next-generation antipsychotic that may be effective in treating schizophrenia patients. Schizophrenia impacts more than five million people in the G7 (U.S., France, Germany, Italy, Spain, United Kingdom, and Japan) and a significant opportunity for treatment innovation remains for new and better tolerated therapies. In a Phase 1b study, emraclidine has shown promising efficacy and safety in schizophrenia and is currently completing two Phase 2 trials that were designed to be registration enabling. In addition, emraclidine has potential in dementia-related psychosis in Alzheimer's disease and PD. Emraclidine is currently in a Phase 1 study in elderly healthy volunteers in support of a potential Alzheimer's disease psychosis program.
In addition to emraclidine, Cerevel has multiple assets advancing in clinical development with best-in-class potential that are complementary to AbbVie's priority areas within neuroscience. Tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of PD, is currently in Phase 3 studies and has potential for both monotherapy and adjunctive treatment. Tavapadon's efficacy and safety-tolerability profile could enable its utility in early PD, becoming a near-term complementary asset to AbbVie's existing symptomatic therapies for advanced PD. CVL-354, currently in Phase 1, is a potential best-in-class kappa opioid receptor (KOR) antagonist that has the potential to provide significantly improved efficacy and tolerability compared to existing treatments for major depressive disorder (MDD). Darigabat, currently in Phase 2, is an alpha 2/3/5 selective GABAA receptor PAM for treatment-resistant epilepsy and panic disorder.
AbbVie will acquire all outstanding Cerevel common stock for $45.00 per share in cash. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Cerevel shareholders. The proposed transaction is expected to be accretive to adjusted diluted earnings per share (EPS) beginning in 2030.
Read also: AbbVie to acquire ImmunoGen, including its flagship cancer therapy Elahere
1 year 4 months ago
News,Neurology and Neurosurgery,Neurology & Neurosurgery News,Industry,Pharma News,Latest Industry News
KFF Health News' 'What the Health?': Democrats See Opportunity in GOP Threats to Repeal Health Law
The Host
Julie Rovner
KFF Health News
Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A to Z,” now in its third edition.
With other GOP presidential candidates following Donald Trump’s lead in calling for an end to the Affordable Care Act, Democrats are jumping on an issue they think will favor them in the 2024 elections. The Biden administration almost immediately rolled out a controversial proposal that could dramatically decrease the price of drugs developed with federally funded research dollars. The drug industry and the business community at large are vehemently opposed to the proposal, but it is likely to be popular with voters.
Meanwhile, the Supreme Court hears arguments in a case to decide whether the Sackler family should be able to shield billions of dollars taken from its bankrupt drug company, Purdue Pharma, from further lawsuits regarding the company’s highly addictive drug OxyContin.
This week’s panelists are Julie Rovner of KFF Health News, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Rachana Pradhan of KFF Health News.
Panelists
Anna Edney
Bloomberg
Alice Miranda Ollstein
Politico
Rachana Pradhan
KFF Health News
Among the takeaways from this week’s episode:
- The ACA may end up back on the proverbial chopping block if Trump is reelected. But as many in both parties know, it is unlikely to be a winning political strategy for Republicans. ACA enrollment numbers are high, as is the law’s popularity, and years after a failed effort during Trump’s presidency, Republicans still have not unified around a proposal to replace it.
- Democrats are eager to capitalize on the revival of “repeal and replace.” This week, the Biden administration announced plans to exercise so-called “march-in rights,” which it argues allow the government to seize certain patent-protected drugs whose prices have gotten too high and open them to price competition. The plan, once largely embraced by progressives, could give President Joe Biden another opportunity to claim his administration has proven more effective than Trump’s heading into the 2024 election.
- The Senate voted to approve more than 400 military promotions this week, effectively ending the 10-month blockade by Republican Sen. Tommy Tuberville of Alabama over a Pentagon policy that helps service members travel to obtain abortions. At the state level, the Texas courts are considering cases over its exceptions to the state’s abortion ban, while in Ohio, a woman who miscarried after being sent home from the hospital is facing criminal charges.
- Meanwhile, the Supreme Court soon could rule on whether EMTALA, or the Emergency Medical Treatment and Active Labor Act, requires doctors to perform abortions in emergencies. And justices are also considering whether to allow a settlement deal to move forward that does not hold the Sacker family accountable for the harm caused by opioids.
- “This Week in Medical Misinformation” highlights a lawsuit filed by Texas Attorney General Ken Paxton accusing Pfizer of failing to end the covid-19 pandemic with its vaccine.
Also this week, Rovner interviews Dan Weissmann, host of KFF Health News’ sister podcast, “An Arm and a Leg,” about his investigation into hospitals suing their patients for unpaid medical bills.
Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too:
Julie Rovner: The Wisconsin State Journal’s “Dane, Milwaukee Counties Stop Making Unwed Fathers Pay for Medicaid Birth Costs,” by David Wahlberg.
Anna Edney: Bloomberg News’ “Tallying the Best Stats on US Gun Violence Is Trauma of Its Own,” by Madison Muller.
Alice Miranda Ollstein: Stat’s “New Abortion Restrictions Pose a Serious Threat to Fetal Surgery,” by Francois I. Luks, Tippi Mackenzie, and Thomas F. Tracy Jr.
Rachana Pradhan: KFF Health News’ “Patients Expected Profemur Artificial Hips to Last. Then They Snapped in Half,” by Brett Kelman and Anna Werner, CBS News.
Also mentioned in this week’s episode:
- Bloomberg News’ “The Pentagon Wants to Root Out Shoddy Drugs. The FDA Is in Its Way,” by Anna Edney and Riley Griffin.
- Ars Technica’s “Texas Sues Pfizer With COVID Anti-Fax Argument That Is Pure Stupid,” by Beth Mole.
Click to open the transcript
Transcript: Democrats See Opportunity in GOP Threats to Repeal Health Law
KFF Health News’ ‘What the Health?’Episode Title: Democrats See Opportunity in GOP Threats to Repeal Health LawEpisode Number: 325Published: Dec. 7, 2023
[Editor’s note: This transcript was generated using both transcription software and a human’s light touch. It has been edited for style and clarity.]
Julie Rovner: Hello, and welcome back to “What the Health?” I’m Julie Rovner, chief Washington correspondent for KFF Health News, and I’m joined by some of the best and smartest reporters in Washington. We’re taping this week on Thursday, Dec. 7, at 10 a.m. As always, news happens fast, and things might’ve changed by the time you hear this. So here we go. Today, we are joined via video conference by Alice Miranda Ollstein of Politico.
Alice Miranda Ollstein: Good morning.
Rovner: Anna Edney of Bloomberg News.
Anna Edney: Hello.
Rovner: And my KFF Health News colleague Rachana Pradhan.
Rachana Pradhan: Good morning, Julie.
Rovner: Later in this episode we’ll have my interview with Dan Weissmann, host of our sister podcast, “An Arm and a Leg.” Dan’s been working on a very cool two-part episode about hospitals suing their patients that he will explain. But first, this week’s news. So now that former President [Donald] Trump has raised the possibility of revisiting a repeal of the Affordable Care Act, all of the other Republican presidential wannabes are adding their two cents.
Florida Gov. Ron DeSantis says that rather than repeal and replace the health law, he would “repeal and supersede,” whatever that means. Nikki Haley has been talking up her anti-ACA bona fides in New Hampshire, and the leading Republican candidate for Senate in Montana is calling for a return to full health care privatization, which would mean getting rid of not only the Affordable Care Act, but also Medicare and Medicaid.
But the Affordable Care Act is more popular than ever, at least judging from this year’s still very brisk open enrollment signups. Alice, you wrote an entire story about how the ACA of 2023 is not the ACA of 2017, the last time Republicans took a serious run at it. How much harder would it be to repeal now?
Ollstein: It would be a lot harder. So, not only have a bunch of red and purple states expanded Medicaid since Republicans took their last swing at the law — meaning that a bunch more constituents in those states are getting coverage they weren’t getting before and might be upset if it was threatened by a repeal — but also just non-Medicaid enrollment is up as well, fueled in large part by all the new subsidies that were implemented over the last few years. And that’s true even in states that resisted expansions.
DeSantis’ Florida, for instance, has the highest exchange enrollment in the country. There’s just a lot more people with a lot more invested in maintaining the program. You have that higher enrollment, you have the higher popularity, and we still haven’t seen a real replacement or “supersede” plan, or whatever they want to call it. And folks I talk to on Capitol Hill, Republican lawmakers, even those that were pretty involved last time, do not think such a plan is coming.
Rovner: It did get asked about at the “last” Republican presidential primary debate last night, and there was an awful lot of hemming and hawing about greedy drug companies and greedy insurance companies, and I heard exactly nothing about any kind of plan. Has anybody else seen any sign of something that Republicans would actually do if they got rid of the Affordable Care Act?
Pradhan: No. There was a time, immediately after the ACA’s passage, that health care was a winning political issue for Republicans, right? It was multiple election cycles that they capitalized on Obamacare and used it to regain House majorities, Senate majorities, and the presidency eventually. But that has not been true for multiple years now. And I think they know that. I think establishment Republicans know that health care is not a winning issue for the party, which is why Democrats are so eager to capitalize on this reopening of ACA repeal, if you will.
Rovner: What a perfect segue, because I was going to say the Biden administration is wasting no time jumping back into health care with both feet, trying to capitalize on what it sees as a gigantic Republican misstep. Just this morning, they are rolling out new proposals aimed at further lowering prescription drug prices, and to highlight the fact that they’ve actually gotten somewhere in some lowering of prescription drug prices.
Now they would like to make it easier to use government “march-in rights,” which would let the government basically tell prescription drug companies, “You’re going to lower your price because we’re going to let other people compete against you, despite your patent.” They’re also doing, and I will use their words, a cross-government public inquiry into corporate greed in health care. Now, some of these things are super controversial. I mean, the march-in rights even before this was unveiled, we saw the drug industry complaining against. But they could also have a real impact if they did some of this, right? Anna, you’ve watched the drug price issue.
Edney: Yeah, I think they definitely could have an impact. This is one of those situations with the march-in rights where we don’t have any clue on where or how exactly, because we haven’t been told that this drug or this class of drugs are kind of what we’re aiming at at this point. It sounds like maybe there’s a little bit more of the plan to be baked, but I am sure there are a lot of progressives, particularly, who had pushed for this that, over the years, who are very excited to even see it mentioned and moving in some sort of way, which hasn’t really happened before.
And, clearly, the Biden administration wants to, like you said, capitalize on health care being part of the campaign. And they’ve done a lot on drug prices, at least a lot in the sense of what can be done. There’s negotiation in Medicare now for some drugs. They kept insulin for Medicare as well. So this is just another step they can say, “We’re doing something else,” and we’d have to see down the line exactly where they’d even plan to use it.
And, of course, as pharma always does, they said that this will hurt innovation and we won’t get any drugs. Not that things have been in place that long, but, clearly, we haven’t seen that so far.
Rovner: Yes, that is always their excuse. I feel like this is one of those times where it doesn’t even matter if any of these things get done, they’re putting them out there just to keep the debate going. This is obviously ground that the Biden campaign would love to campaign on — rather than talking about the economy that makes people mostly unhappy. I assume we’ll be seeing more of this.
Edney: Yeah. Your food prices and other things are very high right now. But if they can talk about getting drug prices lower, that’s a totally different thing that they can point to.
Ollstein: And it’s an easy way to draw the contrast. For people who might be apathetic and think, “Oh, it doesn’t matter who wins the presidential election,” this is an area where the Biden administration can credibly claim, based on what Trump recently said, “This is what’s at stake. This is the difference between my opponent and me. The health care of millions is on the line,” which has been a winning message in past elections.
And what’s been really striking to me is that even talking to a bunch of conservatives now, even though they don’t like the Affordable Care Act, they even are starting to argue that full-scale repeal and replace — now that it’s the status quo — that’s not even a conservative proposal.
They’re saying that it’s more conservative to propose smaller changes that chip around the edges and create some alternatives, but mainly leave it in place, which I think is really interesting, because for so long the litmus test was: Are you for full repeal, root and branch? And we’re just not really hearing that much anymore — except from Trump!
Rovner: The difficulty from the beginning is that the basis of the ACA was a Republican proposal. I mean, they were defanged from the start. It’s been very hard for them to come up with a replacement. What it already is is what Mitt Romney did in Massachusetts. Well, let us turn to the other big issue that Democrats hope will be this coming election year, and that’s abortion, where there was lots of news this week.
We will start with the fact that the 10-month blockade of military promotions by Alabama Republican Sen. Tommy Tuberville is over. Well, mostly over. On Tuesday, the Senate approved by voice vote more than 400 promotions that Tuberville had held up, with only a few four-star nominees still in question. Tuberville’s protests had angered not just Senate Democrats and the Biden administration, who said it was threatening national security, but increasingly his own Senate Republican colleagues.
Tuberville said he was holding up the nominations to protest the Biden administration’s policy of allowing active-duty military members and their dependents to travel out of state for an abortion if they’re stationed where it’s illegal, like in, you know, Alabama. So Alice, what did Tuberville get in exchange for dropping his 10-month blockade?
Ollstein: So, not much. I mean, his aim was to force the Biden administration to change the policy, and that didn’t happen — the policy supporting folks in the military traveling if they’re based in a state where abortion is banned and they need an abortion, supporting the travel to another state, still not paying for the abortion itself, which is still banned. And so that was the policy Tuberville was trying to get overturned, and he did not get that. So he’s claiming that what he got was drawing attention to it, basically. So we’ll see if he tries to use this little bit of remaining leverage to do anything. It does not seem like much was accomplished through this means, although there is a lot of anxiety that this sets a precedent for the future, not just on abortion issues, but, really, could inspire any senator to try to do this and hold a bunch of nominees hostage for whatever policy purpose they want.
Rovner: I know. I mean, senators traditionally sit on nominees for Cabinet posts. And the FDA and the CMS [Centers for Medicare & Medicaid Services] didn’t have a director for, like, three administrations because members were angry at the administration for something about Medicare and Medicaid. But I had never seen anybody hold up military promotions before. This was definitely something new. Rachana, you were going to add something?
Pradhan: Oh, I mean, I was just thinking on Alabama specifically. I mean, I don’t claim to know, even though there was rising anger in Sen. Tuberville’s own party about this move. I mean, I’m not saying I know that this is a factor or not, but in Alabama, regardless of what he tried to do, I think that the attorney general in Alabama has made it clear that he might try to prosecute organizations that help people travel out of state to get abortions.
And so, it’s not like this is only the last word when you’re even talking about military officers or people in the military. Even in his home state, you might see some greater activity on that anyway, which might make it easier for him to honestly, in a way, give it up because it’s not the only way that you could presumably prosecute organizations or people who tried to help others go out of state to access abortion.
Rovner: Yeah, it’s important to say that while he irritated a lot of people in Washington, he probably had a lot of support from people back home in Alabama, which he kept pointing out.
Ollstein: Right. And I saw national anti-abortion groups really cheering him on and urging their members to send him thank-you letters and such. And so definitely not just in his home state. There are conservatives who were backing this.
Rovner: Well, moving on to Texas, because there is always abortion news out of Texas, we have talked quite a bit about the lawsuit filed by women who experienced pregnancy complications and couldn’t get abortions. Well, now we have a separate emergency lawsuit from a woman named Kate Cox, who is currently seeking an abortion because of the threat to her health and life.
Both of these lawsuits aren’t trying to strike the Texas ban, just to clarify when a doctor can perform a medically needed abortion without possibly facing jail time or loss of their medical license. Alice, I know the hearing for Kate Cox is happening even now as we are taping. What’s the status of the other case? We’re waiting to hear from the Texas Supreme Court. Is that where it is?
Ollstein: Yeah. So oral arguments were the other day and a bunch of new plaintiffs have joined the lawsuit. So it’s expanded to a few dozen people now, mostly patients, but some doctors as well who are directly impacted by the law. There was some interesting back and forth in the oral arguments over standing.
And one of the things the state was hammering was that they don’t have standing to sue because they aren’t in this situation that this other woman is in today, where they’re actively pregnant, actively in crisis, and being actively prevented from accessing the health care that they need that their doctor recommends, which in some circumstances is an abortion. And so I think this is an interesting test of the state’s argument on that front.
Rovner: Also, the idea, I mean, that a woman who literally is in the throes of this crisis would step forward and have her name in public and it’s going to court in an emergency hearing today.
Ollstein: Right, as opposed to the other women who were harmed previously. By the time they are seeking relief in court, their pregnancy is already over and the damage has already been done, but they’re saying it’s a threat of a future pregnancy. It’s impacting their willingness to become pregnant again, knowing what could happen, what already happened. But the state was saying like, “Oh, but because you’re not actively in the moment, you shouldn’t have the right to sue.” And so now we’ll see what they say when someone is really in the throes of it.
Rovner: In the moment. Well, another troubling story this week comes from Warren, Ohio, where a woman who experienced a miscarriage is being charged with “abuse of a corpse” because she was sent home from the hospital after her water broke early and miscarried into her toilet, which is gross, but that’s how most miscarriages happen.
The medical examiner has since determined that the fetus was, in fact, born dead and was too premature to survive anyway. Yet the case seems to be going forward. Is this what we can expect to see in places like Ohio where abortion remains legal, but prosecutors want to find other ways to punish women?
Ollstein: I mean, I also think it’s an important reminder that people were criminalized for pregnancy loss while Roe [v. Wade] was still in place. I mean, it was rare, but it did happen. And there are groups tracking it. And so I think that it’s not a huge surprise that it could happen even more now, in this post-Roe era, even in states like Ohio that just voted overwhelmingly to maintain access to abortion.
Pradhan: Julie, do we know what hospital? Because when I was looking at the story, do we know what kind of hospital it was that sent this person away?
Rovner: No. The information is still pretty sketchy about this case, although we do know the prosecutor is sending it to a grand jury. We know that much. I mean, the case is going forward. And we do know that her water broke early and that she did visit, I believe, it was two hospitals, although I have not seen them named. I mean, there’s clearly more information to come about this case.
But yeah, Alice is right. I mean, I wrote about a case in Indiana that was in 2012 or 2013, it was a long time ago, about a woman who tried to kill herself and ended up only killing her fetus and ended up in jail for a year. I mean, was eventually released, but … it’s unusual but not unprecedented for women to be prosecuted, basically, for pregnancy loss.
Ollstein: Yeah, especially people who are struggling with substance abuse. That’s been a major area where that’s happened.
Pradhan: I would personally be very interested in knowing the hospitals that are a part of this and whether they are religiously affiliated, because there’s a standard of care in medicine for what happens if you have your water break before the fetus is viable and what’s supposed to happen versus what can happen.
Rovner: There was a case in Michigan a few years ago where it was a Catholic hospital. The woman, her water broke early. She was in a Catholic hospital, and they also sent her home. I’m trying to remember where she finally got care. But yeah, that has been an issue also over the years. Well, meanwhile, back here in Washington, the Supreme Court is likely to tell us shortly, I believe, whether the 1986 Emergency Medical Treatment and Active Labor Act, known as EMTALA, requires doctors to perform abortions in life-threatening situations, as the Biden administration maintains.
Alice, this case is on what’s known as the “shadow docket” of the Supreme Court, meaning it has not been fully briefed and argued. It’s only asking if the court will overturn a lower court’s ruling that the federal law trumps the state’s ban. When are we expecting to hear something?
Ollstein: It could be after justices meet on Friday. Really, it could be whenever after that. As we’ve seen in the last few years, the shadow docket can be very unpredictable, and we could just get, at very odd times, major decisions that impact the whole country or just one state. And so, yes, I mean, this issue of abortion care and emergency circumstances is playing out in court in a couple different states, and the federal government is getting involved in some of those states.
And so I think this could be a big test. Unlike a lot of lawsuits going on right now, this is not seeking to strike down the state’s abortion ban entirely. It’s just trying to expand and clarify that people who are in the middle of a medical emergency shouldn’t be subject to the ban.
Rovner: It’s similar to what they’re fighting about in Texas, actually.
Ollstein: Yeah, exactly. And this is still playing out at the 9th Circuit, but they’re trying to leapfrog that and get the Supreme Court to weigh in the meantime.
Rovner: Yeah, and we shall see. All right, well, while we’re on the subject of “This Week in Court,” let us move on to the case that was argued in public at the Supreme Court this week about whether the Sackler family can keep much of its wealth while declaring bankruptcy for its drug company, Purdue Pharma, that’s been found liable for exacerbating, if not causing much of the nation’s opioid epidemic.
The case involves basically two bad choices: Let the Sacklers manipulate the federal bankruptcy code to shield billions of dollars from future lawsuits or further delay justice for millions of people injured by the company’s behavior. And the justices themselves seem pretty divided over which way to go. Anna, what’s at stake here? This is a lot, isn’t it?
Edney: Yeah. I mean, it’s interesting how it doesn’t exactly break down on ideological lines. The justices were — I don’t want to say all over the place, because that sounds disrespectful — but they had concerns on many different levels. And one is that the victims and their lawyers negotiated the settlement because for them it was the best way they felt that they could get compensation, and they didn’t feel that they could get it without letting the Sacklers off the hook, that the Sacklers basically would not sign the settlement agreement, and they were willing to go that route.
And the government is worried about using that and letting the Sacklers off the hook in this way and using this bankruptcy deal to be able to shield a lot of their money that they took out of the company, essentially, and have in their personal wealth now. And so that’s something that a lot of companies are, not a lot, but companies are looking to hope to use the sign of bankruptcy protection when it comes to big class-action lawsuits and harm to consumers.
And so I think that what the worry is is that that then becomes the precedent, that the ones at the very top will always get off because it’s easier to negotiate the settlement that way.
Rovner: We’ll obviously have to wait until — as this goes a few months — to see the decisions in this case, but it’s going to be interesting. I think everybody, including the justices, are unhappy with the set of facts here, but that’s why it was in front of the Supreme Court. So our final entry in “This Week in Court” is a twofer. It is also “This Week in Health Misinformation.”
Texas Attorney General Ken Paxton has filed suit against Pfizer for allegedly violating Texas’ Deceptive Trade Practices Act because its covid vaccine did not, in fact, end the covid epidemic. Quoting from the attorney general’s press release, “We are pursuing justice for the people of Texas, many of whom were coerced by tyrannical vaccine mandates to take a defective product sold by lies.” It’s hard to even know where to start with this, except that, I guess, anyone can sue anyone for anything in Texas, right?
Edney: Yeah, that’s a very good point. The entire concept of it feels so weird. I mean, a vaccine doesn’t cure anything, right? That’s not the point of a vaccine. It’s not a drug. It is a vaccine that is supposed to prevent you from getting something, and not everybody took it. So that feels like the end of the story, but, clearly, the attorney general would prefer attention, I think, on this, and to continue to sow doubt in vaccines and the government and the Food and Drug Administration seems to be maybe more of the point here.
Rovner: I noticed he’s only suing for, I think, it’s $10 million, which is frankly not a ton of money to a company as big as Pfizer. So one would assume that he’s doing this more for the publicity than for the actual possibility of getting something.
Pradhan: Yeah, I think Pfizer’s CEO’s annual salary is more than the damages that are being sought in this case. So it’s really not very much money at all. I mean, more broadly speaking, I mean, Texas, Florida, I think you see especially post-public-health-emergency-covid times, the medical freedom movement has really taken root in a lot of these places.
And I think that it just seems like this is adding onto that, where doctors say they should be able to give ivermectin to covid patients and it helped them and not be at risk of losing their license. And that’s really kind of an anti-vaccine sentiment. Obviously, it’s very alive and well.
Rovner: We are post-belief-in-scientific-expertise.
Edney: Well, I was going to say, I appreciated The Texas Tribune’s story on this because they called out every time in this lawsuit that he was twisting the truth or just completely not telling the truth at all in the sense that he said that more people who took the vaccine died, and that’s clearly not the case. And so I appreciated that they were trying to call him out every time that he said something that wasn’t true, but was just completely willing to put that out in the public sphere as if it was.
Rovner: There was also a great story on Ars Technica, which is a scientific website, about how the lawsuit completely misrepresents the use of statistics, just got it completely backwards. We’ll post a link to that one too. Well, while we are talking about drug companies, let’s talk about some drugs that really may not be what companies say they are.
Anna, you have a new story up this week about the Pentagon’s effort to ensure that generic drugs are actually copies of the drugs they’re supposed to be. That effort’s running into a roadblock. Tell us a little about that.
Edney: Yeah, thanks for letting me talk about this one. It’s “The Pentagon Wants to Root Out Shoddy Drugs. The FDA Is in Its Way.” So the FDA is the roadblock to trying to figure out whether the drugs, particularly that the military and their family members are taking, work well and don’t have side effects that could be extremely harmful. So what’s going on here is that the Defense Department and others, the White House even, has grown skeptical of the FDA’s ability to police generic drugs, largely that are made overseas.
We did some analysis and we found that it was actually 2019 was the first time that generic drug-making facilities in India surpassed the number of those in the U.S. So we are making more, not just active ingredients, but finished products over in India. And the FDA just doesn’t have a good line into India. They don’t do many unannounced inspections. They usually have to tell the company they’re coming weeks in advance. And what we found is when the Defense Department started looking into this, they partnered with a lab to test some of these drugs.
They got some early results. Those results were concerning, as far as the drug might not work, and also could cause kidney failure, seizures. And even despite this, they’ve been facing the FDA around every corner trying to stop them and trying to get them not to test drugs. They say it’s a waste of money, when, in fact, Kaiser Permanente has been doing this for its 12.7 million members for several years.
And it just seems like something is going on at the FDA and that they don’t want people to have any questions about generic drugs. They really just want everyone to accept that they’re always exactly the same, and they even derail the White House effort to try to look into this more as well. But the Pentagon said, “Thank you very much, FDA, but we’re going forward with this.”
Rovner: Yeah. I mean, I could see that the FDA would be concerned about … they’re supposed to be the last word on these things. But, as you point out and as much of your reporting has pointed out over the last couple of years, the FDA has not been able to keep up with really making sure that these drugs are what they say they are.
Edney: One thing I learned that was interesting, and this is that in Europe, actually, there’s a network of 70 labs that do this kind of testing before drugs reach patients and after they reach patients. So it’s not a totally unusual thing. And for some reason, the FDA does not want that to happen.
Rovner: Well, finally on the drug beat this week, CVS announced earlier that it would overhaul its drug pricing to better reflect how much it pays for the drugs, all of which sounds great, but the fact is that how much CVS pays for the drugs doesn’t have all that much effect on how much we end up paying CVS for those same drugs, right? They’re just changing how they get the drugs from the manufacturers, not necessarily how they price it for the customers.
Pradhan: I think my main question would be, what does that mean for a patient’s out-of-pocket cost for prescriptions? I don’t know how much of this has to do with … for CVS as the pharmacy, but we have CVS Caremark, which is a major PBM, and how this affects the pricing models there. And PBMs, of course, have been under scrutiny in Congress. And there’s outside pressure too, right? The story that you highlighted, Julie, talks about Mark Cuban’s affordable-drug effort. And so, yeah, I don’t know. I mean, I think it sounds good until maybe we see some more details, right?
Rovner: I saw one story that said, “This could really help lower drug prices for consumers,” and one that said, “This could actually raise drug prices for consumers.” So I’m assuming that this is another one where we’re going to have to wait and see the details of. All right, well, that is this week’s news.
Now we will play my interview with Dan Weissmann of the “Arm and a Leg” podcast, and then we will come back with our extra credits. I am pleased to welcome back to the podcast Dan Weissmann, host of KFF Health News’s sister podcast, “An Arm and a Leg.” Dan has a cool two-part story on hospitals suing patients for overdue bills that he’s here to tell us about. Dan, welcome back.
Dan Weissmann: Julie, thanks so much for having me.
Rovner: So over the past few years, there have been a lot of stories about hospitals suing former patients, including a big investigation by KFF Health News. But you came at this from kind of a different perspective. Tell us what you were trying to find out.
Weissmann: We were trying to figure out why hospitals file lawsuits in bulk. Investigative reporters like Jay Hancock at KFF [Health News] have documented this practice, and one of the things that they note frequently is how little money hospitals get from these lawsuits. Jay Hancock compared the amount that VCU [Health] was seeking from patients and compared it to that hospital system’s annual surplus, their profit margin, and it looked tiny. And other studies document essentially the same thing. So why do they do it?
And we got a clue from a big report done by National Nurses United in Maryland, which, in addition to documenting how little money hospitals were getting compared to the million-dollar salaries they were paying executives in this case, also noted that a relatively small number of attorneys were filing most of these lawsuits. Just five attorneys filed two-thirds of the 145,000 lawsuits they documented across 10 years, and just one attorney filed more than 40,000 cases. So we were like, huh, maybe that’s a clue. Maybe we found somebody who is getting something out of this. We should find out more.
Rovner: So you keep saying “we” — you had some help working on this. Tell us about your partners.
Weissmann: Oh my God, we were so, so lucky. We work with The Baltimore Banner, which is a new daily news outlet in Baltimore, new nonprofit news outlet in Baltimore, that specializes in data reporting. Their data editor, Ryan Little, pulled untold numbers of cases, hundreds of thousands of cases, from the Maryland courts’ website and analyzed them to an inch of their life and taught us more than I could ever have imagined.
And Scripps News also came in as a partner and one of their data journalists, Rosie Cima, pulled untold numbers of records from the Wisconsin court system and worked to analyze data that we also got from a commercial firm that has a cache of data that has more detail than what we could pull off the website. It was a heroic effort by those folks.
Rovner: So what did you find? Not what you were expecting, right?
Weissmann: No. While Rosie and Ryan were especially gathering all this data and figuring out what to do with it, I was out talking to a lot of people. And what I found out is that in the main, it appears that frequently when these lawsuits happen and when hospitals file lawsuits in general, they’re not being approached by attorneys. They’re working with collection agencies. And most hospitals do work with a collection agency, and it’s essentially like, I put it like, you get a menu, oh, I’m having a hamburger, I’m going to pursue people for bills.
Like, OK, do you want onions? Do you want mustard? Do you want relish? What do you want on it? And in this case, it’s like, how hard do you want us to go after people? Do you want us to hit their credit reports — if you still can do that, because the CFPB [Consumer Financial Protection Bureau] has been making regulations about that — but do you want us to do that? How often can we call them? And do you want us to file lawsuits if we don’t get results? And so that is essentially in consultation with the hospital’s revenue department and the collection agency, and it’s a strategic decision between them.
That was what we found out through talking to people. What Rosie and Ryan turned up, and the data we had from the folks in New York backed up, is that, surprisingly, in the three states that we looked at, there’s just so much less of this activity than we had expected to find. In Maryland, Ryan sent me a series of emails, the first saying, like, “I’m not actually seeing any this year. That’s got to be wrong. They must be hiding them somewhere. I’m going to go investigate.” And a week later he was like, “I think I found them, and then we’ll go run some more numbers.”
And then a week later, after going to the courthouse and looking at everything you could find, he was like, “No, actually Maryland hospitals just do not seem to be suing anybody this year.” And we had expected there to be fewer lawsuits, but zero was a surprise to everybody. In New York, we appear to have found that two of those three law firms handling all those cases are no longer handling medical bill cases. And in Wisconsin, final numbers are still being crunched. Our second part will have all those numbers.
The Banner is coming out with their numbers this week. But Scripps News and us are still crunching numbers in Wisconsin. But what was the biggest shocker was, I can just tell you, there were so many fewer lawsuits than we had expected, and many of the most active plaintiffs had either cut the practice entirely, like filing zero lawsuits or filing hardly any. One of the things that a lot of these reports that look at across a state, like in New York and the Maryland report, note, and that we found in Wisconsin too, is that most hospitals don’t do this.
Noam Levey at KFF [Health News] found that many hospitals have policies that say, “We might file a lawsuit,” and some larger number of hospitals file some lawsuits. But in all these cases where you’re seeing tons of lawsuits filed, the phenomenon of suing people in bulk is actually not business as usual for most hospitals. That is driven by a relatively small group of players. There was a study in North Carolina by the state treasurers, obviously and Duke University, that found 95% of all the lawsuits were filed by just a few institutions.
The New York people found this. We’ve seen it in Wisconsin. So I mean, it’s another very interesting question when you’re looking at why does this happen. It’s like it’s not something that most institutions do. And again, in Wisconsin, we found that most of the players that had been the most active had basically stopped.
Rovner: Do we know why? Is it just all of the attention that we’ve seen to this issue?
Weissmann: Probably the answer is we don’t know why. Our colleagues at The Banner called every hospital in Maryland and were not told very much. We emailed all the hospitals in Wisconsin that we could that we had seen dramatically decrease, and nobody came to the phone. So we don’t really know.
But it does seem like, certainly in Maryland and New York, there were these huge campaigns that got tons of publicity and got laws changed, got laws passed. And there has been attention. The reports that Bobby Peterson put out in Wisconsin got attention locally. Sarah Kliff of The New York Times, who’s been writing about these kinds of lawsuits, has written multiple times about hospitals in Wisconsin. So it seems like a good first guess, but it’s a guess. Yeah.
Rovner: Well, one thing that I was interested that you did turn up, as you pointed out at the top, hospitals don’t get very much money from doing this. You’re basically suing people for money that they don’t have. So you did find other ways that hospitals could get reimbursed. I mean, they are losing a lot of money from people who can’t pay, even people with insurance, who can’t pay their multi-thousand-dollar deductible. So what could they be doing instead?
Weissmann: They could be doing a better job of evaluating people’s ability to pay upfront. The majority of hospitals in the United States are obligated by the Affordable Care Act to have charity care policies, financial assistance policies, in which they spell out, if you make less than a certain amount of money, it’s a multiple of the federal poverty level that they choose, we’ll forgive some or all of your bill. And, frequently, that number is as much as four times the federal poverty level. They might knock 75% off your bill, which is a huge help.
And as a guy that I met noted, using data from KFF, 58% of Americans make less than 75% of the federal poverty level. That is a lot of people. And so if you’re chasing someone for a medical bill, they might very well have been someone you could have extended financial assistance to. This guy, his name is Nick McLaughlin, he worked for 10 years for a medical bill collections agency. Someone in his family had a medical bill they were having a hard time paying, and he figured out that they qualified for charity care, but the application process, he noted, was really cumbersome, and even just figuring out how to apply was a big process. And so he thought, I know that chasing people for money they don’t have isn’t really the best business model and that we’re often chasing people for money they don’t have. What if we encourage hospitals to be more proactive about figuring out if someone should be getting charity care from them in the first place?
Because, as he said, every time you send someone a bill, you’re spending two bucks. And you’re not just sending one bill, you’re sending like three bills and a final notice. That all adds up, and you’re manning a call center. You’re spending money and you’re missing opportunities by not evaluating people. Because while you’re asking about their income, you might find out they’re eligible for Medicaid, and you can get paid by Medicaid rather than chasing them for money they don’t have.
And two, they might update their insurance information from you and you can get money from their insurance. You can extend financial assistance to somebody, as you said, who has a deductible they can’t pay, and they might actually come to you for care that you can unlock money from their insurance if they’re going to come to you because they’re not afraid of the bill.
I should absolutely say, while Nick McLaughlin is selling hospitals on the idea of adopting new software, which is a great idea, they should do that, they should be more proactive, an entity called Dollar For, a nonprofit organization out of the Pacific Northwest that’s been doing work all over the country, has been beating the drum about this and has a tool that anybody can use.
Essentially, go to their website, dollarfor.org, and type in where you were seen and an estimate of your income, and they will tell you, you’re likely to qualify for charity care at this hospital, because they have a database of every hospital’s policy. And if you need help applying, because some of these applications are burdensome, we’ll help you. So this exists, and everybody should know about it and everybody should tell everybody they know about it. I think the work they’re doing is absolutely heroic.
Rovner: Well, Dan Weissmann, thank you so much for joining us. We will post a link to Dan’s story in our show notes and on our podcast page.
Weissmann: Julie, thanks so much for having me.
Rovner: OK, we are back. And it’s time for our extra-credit segment. That’s when we each recommend a story we read this week we think you should read, too. As always, don’t worry if you miss it. We will post the links on the podcast page at kffhealthnews.org and in our show notes on your phone or other mobile device. Anna, why don’t you go first this week?
Edney: Sure. This is from my colleague Madison Muller, “Tallying the Best Stats on US Gun Violence Is Trauma of Its Own.” And I thought she just did such an amazing job with this story, talking to Mark Bryant, who helped start an organization, Gun Violence Archive, which is essentially the only place that is trying to tally every instance of gun violence.
And because of a lot of the restrictions that the NRA has helped get into government regulations and things, some of them which are more recently loosening, but because of those in the past, this is really the only way you could try to look up these statistics. And he’s just given the last decade of his life, with no breaks, trying to do this and his health is failing. And I thought it was just a really poignant look at somebody who has no skin in the game, but just wanted the right information out there.
Rovner: Yeah, obviously this is a big deal. Alice.
Ollstein: I did an op-ed that was published in Stat by a group of fetal medicine specialists who are writing about how their work is being compromised by state abortion bans right now. They were saying these are very risky, high-stakes procedures where they perform operations in utero, latent pregnancy usually, and it’s an attempt to save the pregnancy where there is a big risk. But with all of these, there are risks that it could end the pregnancy, and now they’re afraid of being prosecuted for that.
And they describe a bunch of challenging situations that, even without these bans are challenging, things where there’s twins and something to help one could harm the other twin, and this could all affect the health and life of the parent as well. And so they’re saying that they’re really in this whole new era and have to think about the legal risks, as well as the medical and bioethical ones that they already have to deal with.
Rovner: I’ve reported about this over the years, and I can tell you that these are always really wrenching family decisions about trying to desperately save a pregnancy by doing this extraordinarily difficult and delicate kind of procedure. Rachana.
Pradhan: My extra credit is a story from our colleague Brett Kelman, who worked on this investigation with CBS News. It is about a type of artificial hip known as Profemur that literally were snapping in half in patients’ bodies. I told Brett earlier this week that I was cringing at every line that I read. So if folks want to get a really, frankly, pretty gruesome, awful story about how people around the country have received these artificial hips, and the fact that they broke inside their bodies has really caused a lot of damage.
And, frankly, I know we talked about the FDA, but also this story really sheds light on how the FDA has dropped the ball in not acting with more urgency. And had they done that, many of these injuries likely would’ve been avoided. So, I urge everyone to read it. It’s a great story.
Rovner: It is. I also flinched when I was reading a lot of it. Well, my story is from the Wisconsin State Journal by David Wahlberg, and it’s called “Dane, Milwaukee Counties Stop Making Unwed Fathers Pay for Medicaid Birth Costs.” And while I have been covering Medicaid since the 1980s, and I never knew this even existed, it seems that a handful of states, Wisconsin among them, allows counties to go after the fathers of babies born on Medicaid, which is about half of all births — Medicaid’s about half of all births.
Not surprisingly, making moms choose between disclosing the father to whom she is not married to the state or losing Medicaid for her infant is not a great choice. And there’s lots of research to suggest that it can lead to bad birth outcomes, particularly in African American and Native American communities. I have long known that states can come after the estates of seniors who died after receiving Medicaid-paid nursing home or home care, but this one, at the other end of life, was a new one to me.
Now, I want to know how many other states are still doing this. And when I find out, I’ll report back.
OK, that is our show. As always, if you enjoy the podcast, you can subscribe wherever you get your podcast. We’d appreciate it if you left us a review. That helps other people find us too. Thanks, as always, to our tireless tech guru, Francis Ying, who’s back from vacation. Also, as always, you can email us your comments or questions. We’re at whatthehealth@kff.org, or you can still find me at X, @jrovner, or @julierovner at Bluesky and Threads. Anna?
Edney: @anna_edneyreports on Threads and @annaedney on X.
Rovner: Rachana.
Pradhan: I’m @rachanadpradhan on X.
Rovner: Alice.
Ollstein: I’m @AliceOllstein on X, and @AliceMiranda on Bluesky.
Rovner: We will be back in your feed next week. Until then, be healthy.
Credits
Francis Ying
Audio producer
Emmarie Huetteman
Editor
To hear all our podcasts, click here.
And subscribe to KFF Health News’ “What the Health?” on Spotify, Apple Podcasts, Pocket Casts, or wherever you listen to podcasts.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.
USE OUR CONTENT
This story can be republished for free (details).
1 year 4 months ago
Elections, Health Care Costs, Health Care Reform, Health Industry, Medicaid, Medicare, Multimedia, States, Abortion, Biden Administration, FDA, KFF Health News' 'What The Health?', Legislation, Obamacare Plans, Podcasts, Women's Health